Key Highlights:Tegoprazan is the first and only P-CAB reported to demonstrate clinical improvement in both hallmark symptoms of NERD, heartburn and regurgitation, in a prospective U.S. phase 3 clinical trial.Detailed analysis from the randomized, double-blind, placebo-controlled Phase 3…
New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of prior antibody status, in adult patients with moderate to severely active Crohn's disease and ulcerative colitisLate-breaking analysis shows significantly higher rates of clinical remission…
LOS ANGELES, Oct. 10, 2026 /PRNewswire/ -- On World Mental Health Day, October 10, Scientology Network presents a marathon event spotlighting the Citizens Commission on Human Rights (CCHR). The program features CCHR's mission to expose psychiatric industry corruption…
The new award brings together a team of scientists who will combine AI, large-scale experiments and human-cell studies to predict harmful protein changes before disease takes hold.KANSAS CITY, Mo., Oct. 9, 2026 /PRNewswire/ -- Neurodegenerative diseases such as…
Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead, Cancer Vaccines at Moderna, join Everest MedicinesAppointments support continued advancement of Everest's mRNA pipeline,…
COLUMBIA, Md., Oct. 8, 2026 /PRNewswire/ -- MedSTAR Transport, MedStar Health's critical care transport program, is introducing a new Airbus H145 D3 helicopter to strengthen its ability to transport critically ill and injured patients across the Washington, D.C.,…
CAESAREA, Israel, Oct. 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the addition…
UPPSALA, Sweden, Oct. 6, 2026 /PRNewswire/ -- Beactica Therapeutics AB, a Swedish precision medicine company, today announced the selection of BEA-28 as a preclinical candidate for its TEAD programme, which is aimed at developing novel therapies for a…
LAS VEGAS, Oct. 4, 2026 /PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine through education and research, today announced results from the Late-Breaking Clinical Trials presented at The VEINS 2026 conference,…
First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a monogenic disease.Paired muscle biopsies reveal 3.5- to 5.3-fold increases in sarcolemmal utrophin expression,…